|
1
|
Aggarwal BB, Shishodia S, Sandur SK, et
al: Inflammation and cancer: how hot is the link? Biochem
Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O’Hayre M, Salanga CL, Handel TM, et al:
Chemokines and cancer: migration, intracellular signalling and
intercellular communication in the microenvironment. Biochem J.
409:635–649. 2008.PubMed/NCBI
|
|
3
|
Yamashita H, Takahashi Y, Kano T, et al:
Malignant lymphoma presenting as inflammation of unknown origin.
Nihon Rinsho Meneki Gakkai Kaishi. 35:136–143. 2012.(In
Japanese).
|
|
4
|
Aldinucci D, Gloghini A, Pinto A, et al:
The classical Hodgkin’s lymphoma microenvironment and its role in
promoting tumor growth and immune escape. J Pathol. 221:248–263.
2010.
|
|
5
|
Küppers R: The biology of Hodgkin’s
lymphoma. Nat Rev Cancer. 9:15–27. 2009.
|
|
6
|
Kim SH, Choi EY, Shin YK, et al:
Generation of cells with Hodgkin’s and Reed-Sternberg phenotype
through downregulation of CD99 (Mic2). Blood. 92:4287–4295.
1998.
|
|
7
|
Kim SH, Shin YK, Lee IS, et al: Viral
latent membrane protein1 (LMP-1)-induced CD99 down-regulation in B
cells leads to the generation of cells with Hodgkin’s and
Reed-Sternberg phenotype. Blood. 95:294–300. 2000.
|
|
8
|
Huang X, Zhou X, Wang Z, et al: CD99
triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in
Hodgkin/Reed-Sternberg cells and induces redifferentiation. Int J
Cancer. 131:E382–E394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suh YH, Shin YK, Kook MC, et al: Cloning,
genomic organization, alternative transcripts and expression
analysis of CD99L2, a novel paralog of human CD99, and
identification of evolutionary conserved motifs. Gene. 307:63–76.
2003. View Article : Google Scholar
|
|
10
|
Liu F, Zhang G, Liu F, et al: Effect of
shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in
vitro and in vivo. Oncol Rep. 29:1405–1414.
2013.PubMed/NCBI
|
|
11
|
Matloubian M, David A, Engel S, et al: A
transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo.
Nat Immunol. 1:298–304. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wilbanks A, Zondlo SC, Murphy K, et al:
Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals
elements of CC, CXC, and CX3C chemokines. J Immunol. 166:5145–5154.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hundhausen C, Schulte A, Schulz B, et al:
Regulated shedding of transmembrane chemokines by the disintegrin
and metalloproteinase 10 facilitates detachment of adherent
leukocytes. J Immunol. 178:8064–8072. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruth JH, Haas CS, Park CC, et al:
CXCL16-mediated cell recruitment to rheumatoid arthritis synovial
tissue and murine lymph nodes is dependent upon the MAPK pathway.
Arthritis Rheum. 54:765–778. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morgan AJ, Guillen C, Symon FA, et al:
Expression of CXCR6 and its ligand CXCL16 in the lung in health and
disease. Clin Exp Allergy. 35:1572–1580. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheikine Y, Bang CS, Nilsson L, et al:
Decreased plasma CXCL16/SR-PSOX concentration is associated with
coronary artery disease. Atherosclerosis. 188:462–466. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Conklin L and Alex P: New
serological biomarkers of inflammatory bowel disease. World J
Gastroenterol. 14:5115–5124. 2008. View Article : Google Scholar
|
|
18
|
Verbeke H, Struyf S, Laureys G, et al: The
expression and role of CXC chemokines in colorectal cancer.
Cytokine Growth Factor Rev. 22:345–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ha HK, Lee W, Park HJ, et al: Clinical
significance of CXCL16/CXCR6 expression in patients with prostate
cancer. Mol Med Rep. 4:419–424. 2011.PubMed/NCBI
|
|
20
|
Guo L, Cui ZM, Zhang J, et al: Chemokine
axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node
metastasis in epithelial ovarian carcinoma. Chin J Cancer.
30:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taghizadeh R, Noh M, Huh YH, et al: CXCR6,
a newly defined biomarker of tissue-specific stem cell asymmetric
self-renewal, identifies more aggressive human melanoma cancer stem
cells. PLoS One. 5:e151832010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Darash-Yahana M, Gillespie JW, Hewitt SM,
et al: The chemokine CXCL16 and its receptor, CXCR6, as markers and
promoters of inflammation-associated cancers. PLoS One.
4:e66952009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng MJ, Qiu C, Lai YJ, et al: Application
of immunomagnetic screening strategy for separation of
CD4+and CD8+T cell subpopulations of
peripheral blood. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 13:205–209.
2005.(In Chinese).
|
|
24
|
Zhang Y, Li XZ, Wen ZH, et al:
Relationship between lymphocyte immunophenotypes and histologic
subtypes of Hodgkin’s lymphoma and its significance. Zhongguo Shi
Yan Xue Ye Xue Za Zhi. 17:888–893. 2009.(In Chinese).
|
|
25
|
Bracci PM, Skibola CF, Conde L, et al:
Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk
Lymphoma. 51:497–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aldinucci D, Lorenzon D, Cattaruzza L, et
al: Expression of CCR5 receptors on Reed-Sternberg cells and
Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor
cell growth and microenvironmental interactions. Int J Cancer.
122:769–776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hnátková M, Mociková H, Trnený M, et al:
The biological environment of Hodgkin’s lymphoma and the role of
the chemokine CCL17/TARC. Prague Med Rep. 110:35–41. 2009.
|
|
28
|
Wente MN, Gaida MM, Mayer C, et al:
Expression and potential function of the CXC chemokine CXCL16 in
pancreatic ductal adenocarcinoma. Int J Oncol. 33:297–308.
2008.PubMed/NCBI
|
|
29
|
Hu W, Zhen X, Xiong B, et al: CXCR6 is
expressed in human prostate cancer in vivo and is involved in the
in vitro invasion of PC3 and LNCap cells. Cancer Sci. 99:1362–1369.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsushita K, Toiyama Y, Tanaka K, et al:
Soluble CXCL16 in preoperative serum is a novel prognostic marker
and predicts recurrence of liver metastases in colorectal cancer
patients. Ann Surg Oncol. 19(Suppl 3): S518–S527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanamoto H, Nakayama T, Miyazato H, et al:
Expression of CCL28 by Reed-Sternberg cells defines a major subtype
of classical Hodgkin’s disease with frequent infiltration of
eosinophils and/or plasma cells. Am J Pathol. 164:997–1006.
2004.PubMed/NCBI
|
|
32
|
Deng I, Chen N, Li Y, et al: CXCR6/CXCL16
functions as a regulator in metastasis and progression of cancer.
Biochim Biophys Acta. 1806:42–49. 2010.PubMed/NCBI
|
|
33
|
Jakovic LR, Mihaljevic BS, Perunicic
Jovanovic MD, et al: The prognostic relevance of tumor associated
macrophages in advanced stage classical Hodgkin lymphoma. Leuk
Lymphoma. 52:1913–1919. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Matsumura S, Wang B, Kawashima N, et al:
Radiation-induced CXCL16 release by breast cancer cells attracts
effector T cells. J Immunol. 181:3099–3107. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Machado L, Jarrett R, Morgan S, et al:
Expression and function of T cell homing molecules in Hodgkin’s
lymphoma. Cancer Immunol Immunother. 58:85–94. 2009.
|
